Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Araghchi to Grossi: These parties will bear responsibility for the consequences of their actions
Araghchi to Grossi: Iran will respond to any unlawful action by European countries or parties attempting to turn the Agency into a tool for achieving their objectives
Araghchi to Grossi: We urge the Agency to warn against the consequences of any political move against Iran
Araghchi to Grossi: We call on the Agency to highlight Iran’s full cooperation during the upcoming Board of Governors meeting next week
Araghchi to Grossi: We demand that the Agency reflect the facts in a manner that prevents certain parties from exploiting it to advance their political agendas
Iranian Foreign Minister Abbas Araghchi holds a phone call with IAEA Director General Rafael Grossi
Trump envoy Witkoff has sent 'detailed and acceptable proposal' to Iran for nuclear deal; it's in their best interest to accept it: White House Press Secretary Leavitt
Hamas official says Witkoff's position toward group was 'unfair' and shows 'complete bias' to 'Israel'
Hamas official says it has considered Witkoff's proposal acceptable for negotiations, says 'Israel's' response was incompatible with what the group agreed on
Hamas official says group has not rejected Wikoff's proposal for Gaza ceasefire

Weight loss drug on TikTok, Ozempic, raises concerns among doctors

  • By Al Mayadeen English
  • Source: Agencies
  • 28 Feb 2023 15:12
4 Min Read

Ozempic, a medication created to treat type 2 diabetes, is now a TikTok trend promoted by users for wight loss.

  • x
  • A sample of Ozempic medicine which was initially developed and approved to treat Type 2 diabetes. (AFP)
    A sample of Ozempic medicine that was initially developed and approved to treat Type 2 diabetes (AFP)

Due to its ability to help people lose weight, the diabetes medicine Ozempic has become a social media sensation. However, with its extreme popularity, there are now shortages around the world, and doctors have issued a warning about its potential detrimental effects.

On the social media platform TikTok, where users frequently update followers about their weight loss, videos with the hashtag #Ozempic have almost gathered 600 million views. 

"Losing 40 kilograms (88 pounds) in less than three months is possible" thanks to Ozempic, a French TikToker said with nearly 50,000 views. "It's a miracle," he added.

The injectable medication was initially created and authorized for use in several countries to treat type 2 diabetes by the Danish pharmaceutical company Novo Nordisk. 

When blood glucose levels are high, the drug's active ingredient, semaglutide, binds to the receptors of a hormone that regulates blood sugar and prompts the release of insulin. It lessens appetite by slowing down how rapidly food leaves the stomach. 

Peer-reviewed research in early 2021 found that almost three-quarters of people who used Ozempic lost more than 10% of their body weight.

Since then, Novo Nordisk has created a semaglutide medication with a larger dosage known as Wegovy that is intended to treat obesity and was approved for use in the US in 2021, as well as in Europe and the UK last year.

While Wegovy is still not available with a typical prescription in the UK, France, or a few other nations, Ozempic is. 

Not a magic drug

Jean-Luc Faillie, a pharmacology specialist at France's Montpellier University, said this has resulted in an increase in people who do not have diabetes obtaining prescriptions for Ozempic, as well as "falsified" ones.

Related News

17 Palestinians killed in US-Israeli designated aid zones in Gaza

Shooting on University of Minnesota campus injures 2; suspect detained

Douglas Twenefour, head of care at Diabetes UK, said this drug "is not a medication for people who do not have diabetes or are at risk of type 2 diabetes."

"Stronger than anticipated demand" for Ozempic had led to "intermittent availability and period stock-outs," Novo Nordisk told AFP. 

The company's manufacturing facilities around the world "are now operating 24 hours, seven days a week" to bridge the gap, it added.

Doctors are worried that the rising demand for semaglutide among those looking to lose weight would prevent patients with diabetes from being able to obtain it.

When Wegovy does become accessible, Karine Clement, an expert in obesity at France's INSERM medical research institute, advised that patients strictly adhere to their prescription. 

"It is not a magic drug," she said. "As is always the case with obesity, it must be accompanied with a comprehensive treatment plan."

What are the side effects of Ozempic?

Doctors have also voiced worries about semaglutide's side effects, which Faillie said have not received enough attention.

"Neither patients nor prescribers are motivated to report" the side effects, he said.

The most frequent adverse effect of the medication is nausea. Acute pancreatitis, which can happen even at lower doses, biliary abnormalities, and rare instances of severe constipation that can result in bowel obstruction are some of the more uncommon but serious hazards, according to Faillie. 

He also noted an "increased risk of thyroid cancer" after several years of treatment. While the risks were reasonable considering the benefits for people with diabetes, "there are still uncertainties, particularly in obese patients over the long term," he said.

"If it is used to lose a few kilograms, then the therapeutic benefit is zero," Faillie added.

"That would just be cosmetic, while the risks remain."

  • United States
  • France
  • UK
  • TikTok
  • Drug Trend

Most Read

US judges quietly consider private security amid Trump tensions

US judges quietly consider private security amid Trump pressures

  • US & Canada
  • 25 May 2025
President Donald Trump and Israeli Prime Minister Benjamin Netanyahu arrive to a news conference in the East Room of the White House, Tuesday, Feb. 4, 2025, in Washington (AP)

Rift widens: Trump, Netanyahu clash in heated phone call over Iran

  • Politics
  • 26 May 2025
An Israeli army vehicle moves in the Gaza Strip as seen from southern occupied Palestine, Thursday, May 29, 2025 (AP)

Hamas rejects Witkoff ceasefire plan, says alters terms

  • Politics
  • 29 May 2025
Spokesperson for the Yemeni Armed Forces, Brigadier General Yahya Saree, announces a new operation against Ben Gurion Airport on May 29, 2025 (Yemeni Military Media)

Yemen announces successful hypersonic missile strike on Ben Gurion

  • Politics
  • 30 May 2025

Coverage

All
War on Gaza

Read Next

All
MIT bans class president who gave pro-Palestine speech
US & Canada

MIT bans class president over pro-Palestine speech

Arab ministers condemn Israel 'ban' on planned West Bank visit
Politics

Arab ministers condemn Israeli ban on planned West Bank visit

Major General Hu Gangfeng, Vice President, National Defense University, People's Liberation Army, China, leaves after a panel discussion during the 22nd Shangri-La Dialogue summit in Singapore, Saturday, May 31, 2025. (AP Photo/Anupam Nath)
Politics

China blasts Hegseth, calls US top 'troublemaker' in Asia-Pacific

US activists demand shutdown of Musk's 'dirty' supercomputer: Reports
Technology

US activists demand shutdown of Musk's 'dirty' supercomputer: NBC News

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS